sotalol has been researched along with Obesity in 5 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetic data for the three drugs were qualitatively similar." | 2.68 | Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. ( Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997) |
| " Pharmacokinetic parameters were compared with those obtained previously in non-obese control subjects." | 2.67 | Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ( Barré, J; Cheymol, G; Cohen, A; Hugues, FC; Le Jeunne, C; Poirier, JM, 1990) |
| " In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls." | 1.28 | [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects]. ( Cheymol, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ornelas-Loredo, A | 1 |
| Kany, S | 1 |
| Abraham, V | 1 |
| Alzahrani, Z | 1 |
| Darbar, FA | 1 |
| Sridhar, A | 1 |
| Ahmed, M | 1 |
| Alamar, I | 1 |
| Menon, A | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Konda, S | 1 |
| Darbar, D | 1 |
| Zakrzewska-Koperska, J | 1 |
| Urbanek, P | 1 |
| Szufladowicz, E | 1 |
| Bodalski, R | 1 |
| Szumowski, Ł | 1 |
| Maryniak, A | 1 |
| Walczak, F | 1 |
| Cheymol, G | 3 |
| Poirier, JM | 2 |
| Carrupt, PA | 1 |
| Testa, B | 1 |
| Weissenburger, J | 1 |
| Levron, JC | 1 |
| Snoeck, E | 1 |
| Le Jeunne, C | 1 |
| Cohen, A | 1 |
| Barré, J | 1 |
| Hugues, FC | 1 |
2 trials available for sotalol and Obesity
| Article | Year |
|---|---|
Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Adult; Area Under Curve; Benzopyrans; Binding Sites; Bi | 1997 |
Comparison of propranolol and sotalol pharmacokinetics in obese subjects.
Topics: Adult; Blood Pressure; Cardiac Output; Chromatography, High Pressure Liquid; Creatinine; Female; Hea | 1990 |
3 other studies available for sotalol and Obesity
| Article | Year |
|---|---|
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diet, High-Fat; Disease Models, Animal; | 2020 |
[Next cardioversion or RF ablation in professional driver with recurrent typical atrial flutter and MAS syndromes].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Automobile Driving; Catheter Ablation; Electrocardiog | 2009 |
[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Female; Humans; Male; Obesity; Propanolamines; Propr | 1990 |